Cyclerion Therapeutics (CYCN) Income from Continuing Operations (2018 - 2025)
Cyclerion Therapeutics (CYCN) posted quarterly Income from Continuing Operations of 1006000.0 for Q3 2025, up 10.82% year-over-year from 907814.4 in Q3 2024, and up 39.83% quarter-over-quarter from 1672000.0 in Q2 2025.
Cyclerion Therapeutics (CYCN) Income from Continuing Operations (2018 - 2025) Analysis & Trends
Cyclerion Therapeutics' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 1006000.0 for Q3 2025.
- In Q3 2025, Income from Continuing Operations rose 10.82% year-over-year to 1006000.0; the TTM figure through Sep 2025 stood at 3633000.0 (up 38.68% YoY), while the FY2024 annual figure was 86784000.0, up 9.02% from the prior year.
- Income from Continuing Operations for Q3 2025 stood at 1006000.0, up from 1672000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 502000.0 in Q4 2024, with the low at 18488000.0 in Q2 2021.
- The 5-year median for Income from Continuing Operations is 3375000.0 (2023), against an average of 6219684.21.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations dropped 29.61% in 2023, then surged 127.97% in 2024.
- Cyclerion Therapeutics' Income from Continuing Operations stood at 15725000.0 in 2021, then soared by 71.67% to 4455000.0 in 2022, then soared by 59.71% to 1795000.0 in 2023, then soared by 127.97% to 502000.0 in 2024, then sank by 300.4% to 1006000.0 in 2025.
- Business Quant data shows CYCN's Income from Continuing Operations at 1006000.0 in Q3 2025, 1672000.0 in Q2 2025, and 1457000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Cyclerion Therapeutics | 12.71 Mn | 9.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1.01 Mn |
| Jun 30, 2025 | -1.67 Mn |
| Mar 31, 2025 | -1.46 Mn |
| Dec 31, 2024 | 502,000.00 |
| Sep 30, 2024 | -1.13 Mn |
| Jun 30, 2024 | -1.38 Mn |
| Mar 31, 2024 | -1.62 Mn |
| Dec 31, 2023 | -1.80 Mn |
| Sep 30, 2023 | -6.12 Mn |
| Jun 30, 2023 | -1.97 Mn |
| Mar 31, 2023 | -3.38 Mn |
| Dec 31, 2022 | -4.46 Mn |
| Sep 30, 2022 | -4.72 Mn |
| Jun 30, 2022 | -13.63 Mn |
| Mar 31, 2022 | -13.18 Mn |
| Dec 31, 2021 | -15.73 Mn |
| Sep 30, 2021 | -12.16 Mn |
| Jun 30, 2021 | -18.49 Mn |
| Mar 31, 2021 | -14.80 Mn |
| Dec 31, 2020 | -20.56 Mn |